Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report

The coronavirus pandemic is one of the most significant public health events in recent history. Currently, no specific treatment is available. Some drugs and cell-based therapy have been tested as alternatives to decrease the disease’s symptoms, length of hospital stay, and mortality. We reported th...

Descripción completa

Detalles Bibliográficos
Autores principales: Senegaglia, Alexandra Cristina, Rebelatto, Carmen Lúcia Kuniyoshi, Franck, Claudio Luciano, Lima, Juliana Souza, Boldrini-Leite, Lidiane Maria, Daga, Debora Regina, Leitão, Cleverson Alex, Shigunov, Patrícia, de Azambuja, Ana Paula, Bana, Elisa, Marsaro, Daniela Boscaro, Schaidt, Bruna, Micosky, Andressa, Jamur, Valderez Ravaglio, Schluga, Yara, Vaz, Isadora May, Ribeiro, Lisandro Lima, Correa, Alejandro, Brofman, e Paulo Roberto Slud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175829/
https://www.ncbi.nlm.nih.gov/pubmed/34074163
http://dx.doi.org/10.1177/09636897211021008
Descripción
Sumario:The coronavirus pandemic is one of the most significant public health events in recent history. Currently, no specific treatment is available. Some drugs and cell-based therapy have been tested as alternatives to decrease the disease’s symptoms, length of hospital stay, and mortality. We reported the case of a patient with a severe manifestation of COVID-19 in critical condition who did not respond to the standard procedures used, including six liters of O(2) supplementation under a nasal catheter and treatment with dexamethasone and enoxaparin in prophylactic dose. The patient was treated with tocilizumab and an advanced therapy product based on umbilical cord-derived mesenchymal stromal cells (UC-MSC). The combination of tocilizumab and UC-MSC proved to be safe, with no adverse effects, and the results of this case report prove to be a promising alternative in the treatment of patients with severe acute respiratory syndrome due to SARS-CoV-2.

Ejemplares similares